vs
CASTLE BIOSCIENCES INC（CSTL）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是CASTLE BIOSCIENCES INC的1.6倍（$140.6M vs $87.0M）。VERACYTE, INC.同比增速更快（18.5% vs 0.8%）。VERACYTE, INC.自由现金流更多（$48.8M vs $19.7M）。过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 9.2%）
Castle Biosciences是一家处于商业阶段的诊断企业，专注于开发和商业化针对黑色素瘤等皮肤癌及罕见病的专利临床诊断检测产品，主要服务美国医疗市场，聚焦未被满足的精准诊断需求领域，辅助临床医生制定治疗决策。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
CSTL vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.6倍
$87.0M
营收增速更快
VCYT
高出17.7%
0.8%
自由现金流更多
VCYT
多$29.1M
$19.7M
两年增速更快
VCYT
近两年复合增速
9.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $87.0M | $140.6M |
| 净利润 | — | $41.1M |
| 毛利率 | 79.0% | 72.5% |
| 营业利润率 | -4.4% | 26.4% |
| 净利率 | — | 29.3% |
| 营收同比 | 0.8% | 18.5% |
| 净利润同比 | — | 704.8% |
| 每股收益（稀释后） | $-0.06 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSTLVCYT
| Q4 25 | $87.0M | $140.6M | ||
| Q3 25 | $83.0M | $131.9M | ||
| Q2 25 | $86.2M | $130.2M | ||
| Q1 25 | $88.0M | $114.5M | ||
| Q4 24 | $86.3M | $118.6M | ||
| Q3 24 | $85.8M | $115.9M | ||
| Q2 24 | $87.0M | $114.4M | ||
| Q1 24 | $73.0M | $96.8M |
净利润CSTLVCYT
| Q4 25 | — | $41.1M | ||
| Q3 25 | $-501.0K | $19.1M | ||
| Q2 25 | $4.5M | $-980.0K | ||
| Q1 25 | $-25.8M | $7.0M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $2.3M | $15.2M | ||
| Q2 24 | $8.9M | $5.7M | ||
| Q1 24 | $-2.5M | $-1.9M |
毛利率CSTLVCYT
| Q4 25 | 79.0% | 72.5% | ||
| Q3 25 | 77.5% | 69.2% | ||
| Q2 25 | 79.5% | 69.0% | ||
| Q1 25 | 81.4% | 69.5% | ||
| Q4 24 | 81.3% | 66.4% | ||
| Q3 24 | 81.8% | 68.2% | ||
| Q2 24 | 83.3% | 68.1% | ||
| Q1 24 | 81.0% | 64.5% |
营业利润率CSTLVCYT
| Q4 25 | -4.4% | 26.4% | ||
| Q3 25 | -8.2% | 17.4% | ||
| Q2 25 | -4.9% | -4.0% | ||
| Q1 25 | -31.7% | 2.5% | ||
| Q4 24 | 4.7% | 3.5% | ||
| Q3 24 | 5.9% | 10.4% | ||
| Q2 24 | 5.8% | 4.0% | ||
| Q1 24 | -7.5% | -4.8% |
净利率CSTLVCYT
| Q4 25 | — | 29.3% | ||
| Q3 25 | -0.6% | 14.5% | ||
| Q2 25 | 5.2% | -0.8% | ||
| Q1 25 | -29.4% | 6.2% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | 2.6% | 13.1% | ||
| Q2 24 | 10.3% | 5.0% | ||
| Q1 24 | -3.5% | -1.9% |
每股收益（稀释后）CSTLVCYT
| Q4 25 | $-0.06 | $0.50 | ||
| Q3 25 | $-0.02 | $0.24 | ||
| Q2 25 | $0.15 | $-0.01 | ||
| Q1 25 | $-0.90 | $0.09 | ||
| Q4 24 | $0.32 | $0.07 | ||
| Q3 24 | $0.08 | $0.19 | ||
| Q2 24 | $0.31 | $0.07 | ||
| Q1 24 | $-0.09 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.5M | $362.6M |
| 总债务越低越好 | $10.1M | — |
| 股东权益账面价值 | $470.9M | $1.3B |
| 总资产 | $578.6M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CSTLVCYT
| Q4 25 | $299.5M | $362.6M | ||
| Q3 25 | $287.5M | $315.6M | ||
| Q2 25 | $275.9M | $219.5M | ||
| Q1 25 | $275.2M | $186.1M | ||
| Q4 24 | $293.1M | $239.1M | ||
| Q3 24 | $95.0M | $274.1M | ||
| Q2 24 | $85.6M | $235.9M | ||
| Q1 24 | $82.9M | $209.2M |
总债务CSTLVCYT
| Q4 25 | $10.1M | — | ||
| Q3 25 | $10.0M | — | ||
| Q2 25 | $10.0M | — | ||
| Q1 25 | $10.0M | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | $10.0M | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $10.0M | — |
股东权益CSTLVCYT
| Q4 25 | $470.9M | $1.3B | ||
| Q3 25 | $467.0M | $1.3B | ||
| Q2 25 | $455.4M | $1.2B | ||
| Q1 25 | $440.3M | $1.2B | ||
| Q4 24 | $455.8M | $1.2B | ||
| Q3 24 | $441.1M | $1.2B | ||
| Q2 24 | $423.9M | $1.1B | ||
| Q1 24 | $402.5M | $1.1B |
总资产CSTLVCYT
| Q4 25 | $578.6M | $1.4B | ||
| Q3 25 | $562.8M | $1.4B | ||
| Q2 25 | $544.7M | $1.3B | ||
| Q1 25 | $501.7M | $1.3B | ||
| Q4 24 | $531.2M | $1.3B | ||
| Q3 24 | $514.6M | $1.3B | ||
| Q2 24 | $487.3M | $1.2B | ||
| Q1 24 | $458.5M | $1.2B |
负债/权益比CSTLVCYT
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.9M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $19.7M | $48.8M |
| 自由现金流率自由现金流/营收 | 22.7% | 34.7% |
| 资本支出强度资本支出/营收 | 8.3% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $28.3M | $126.6M |
8季度趋势，按日历期对齐
经营现金流CSTLVCYT
| Q4 25 | $26.9M | $52.6M | ||
| Q3 25 | $22.6M | $44.8M | ||
| Q2 25 | $20.8M | $33.6M | ||
| Q1 25 | $-6.0M | $5.4M | ||
| Q4 24 | $24.4M | $24.5M | ||
| Q3 24 | $23.3M | $30.0M | ||
| Q2 24 | $24.0M | $29.6M | ||
| Q1 24 | $-6.8M | $-9.0M |
自由现金流CSTLVCYT
| Q4 25 | $19.7M | $48.8M | ||
| Q3 25 | $7.8M | $42.0M | ||
| Q2 25 | $11.6M | $32.3M | ||
| Q1 25 | $-10.8M | $3.5M | ||
| Q4 24 | $16.8M | $20.4M | ||
| Q3 24 | $17.0M | $27.7M | ||
| Q2 24 | $18.8M | $26.8M | ||
| Q1 24 | $-16.0M | $-11.1M |
自由现金流率CSTLVCYT
| Q4 25 | 22.7% | 34.7% | ||
| Q3 25 | 9.4% | 31.8% | ||
| Q2 25 | 13.4% | 24.8% | ||
| Q1 25 | -12.2% | 3.1% | ||
| Q4 24 | 19.5% | 17.2% | ||
| Q3 24 | 19.8% | 23.9% | ||
| Q2 24 | 21.6% | 23.4% | ||
| Q1 24 | -21.9% | -11.5% |
资本支出强度CSTLVCYT
| Q4 25 | 8.3% | 2.7% | ||
| Q3 25 | 17.9% | 2.1% | ||
| Q2 25 | 10.7% | 1.0% | ||
| Q1 25 | 5.4% | 1.6% | ||
| Q4 24 | 8.8% | 3.5% | ||
| Q3 24 | 7.4% | 1.9% | ||
| Q2 24 | 6.0% | 2.4% | ||
| Q1 24 | 12.5% | 2.2% |
现金转化率CSTLVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | 4.60× | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 10.29× | 1.98× | ||
| Q2 24 | 2.69× | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSTL
| Dermatologic | $48.6M | 56% |
| Non Dermatologic | $38.4M | 44% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
